Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that Brett Haumann, M.B.B.Ch., M.B.A., has joined the Aimmune Board of Directors, effective October 31, 2018. Dr. Haumann’s extensive biotech and pharmaceutical leadership experience includes more than 20 years of development and discovery work in allergy and pulmonary medicines.
“I’m excited to welcome Brett to the Aimmune Board,” said Jayson Dallas, M.D., President and CEO of Aimmune. “Brett’s industry experience spans all stages of pharmaceutical drug development, and he has a deep clinical understanding of the allergy and immunology field. His perspective will be a tremendous asset as we lead the way into a new therapeutic space with AR101 for peanut allergy, and as we continue to uncover new scientific insights to improve the lives of those affected by food allergies.”
“It’s an honor to join Aimmune’s Board of Directors,” said Dr. Haumann. “Aimmune is taking a leadership role in understanding and addressing the needs of patients with food allergies. I have been very impressed with their progress in developing a novel oral therapy to treat peanut-allergic patients, as well as the potential that their research pipeline offers to address other food allergies. I look forward to being able to contribute to their continued growth and success at a Board level by applying my insights as a physician and a development scientist.”
Dr. Haumann is Chief Medical Officer and Senior Vice President, Clinical Development, at Theravance Biopharma. Prior to joining Theravance Inc. in 2013, Dr. Haumann served as Chief Medical Officer of the UK allergy company Circassia Limited. He also spent more than a decade with GlaxoSmithKline, where, as Vice President of Clinical Development, he was responsible for late-stage development of medicines for asthma and chronic obstructive pulmonary disease (COPD). He began his industry career with Glaxo Wellcome in the United Kingdom and South Africa, after working as an internal medicine practitioner and clinical researcher in South Africa. Dr. Haumann earned his Bachelor in Medicine and Surgery (M.B.B.Ch.) at the University of Witwatersrand Medical School, South Africa, and he holds an M.B.A. from Open University, United Kingdom.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4–17 years of age. Aimmune plans to submit regulatory filings for marketing approval of AR101 in the United States and Europe based on data from the pivotal Phase 3 PALISADE clinical trial of AR101, which in 4–17-year-old subjects met its primary and key secondary endpoints, and additional ongoing and completed AR101 clinical trials. For more information, please see www.aimmune.com.
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Aimmune’s expectations regarding the potential benefits of AR101; Aimmune’s expectations on regulatory submissions for marketing approval of AR101 for peanut allergy in the United States and Europe, including the timing of these submissions; and Aimmune’s expectations regarding potential applications of the CODIT™ approach to treating life-threatening food allergies. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the expectation that Aimmune will need additional funds to finance its operations; Aimmune’s or any of its collaborative partners’ ability to initiate and/or complete clinical trials; the unpredictability of the regulatory process; the possibility that Aimmune’s or any of its collaborative partners’ clinical trials will not be successful; Aimmune’s dependence on the success of AR101; Aimmune’s reliance on third parties for the manufacture of Aimmune’s product candidates; possible regulatory developments in the United States and foreign countries; and Aimmune’s ability to attract and retain senior management personnel. These and other risks and uncertainties are described more fully in Aimmune’s most recent filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2018. All forward-looking statements contained in this press release speak only as of the date on which they were made. Aimmune undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
This press release concerns a product that is under clinical investigation and that has not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It is currently limited to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.